TY - JOUR T1 - Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1 JF - Anticancer Research JO - Anticancer Res SP - 1683 LP - 1690 DO - 10.21873/anticanres.14120 VL - 40 IS - 3 AU - HAYATO WATANABE AU - TSUTOMU HAYASHI AU - KEISUKE KOMORI AU - KENTARO HARA AU - YUKIO MAEZAWA AU - KAZUKI KANO AU - YOTA SHIMODA AU - HIROHITO FUJIKAWA AU - TORU AOYAMA AU - TAKANOBU YAMADA AU - NAOTO YAMAMOTO AU - HARUHIKO CHO AU - HIROYUKI ITO AU - MANABU SHIOZAWA AU - NORIO YUKAWA AU - SOICHIRO MORINAGA AU - TAKAKI YOSHIKAWA AU - YASUSHI RINO AU - MUNETAKA MASUDA AU - TAKASHI OGATA AU - TAKASHI OSHIMA Y1 - 2020/03/01 UR - http://ar.iiarjournals.org/content/40/3/1683.abstract N2 - Background: This study aimed to investigate the impact of postoperative complications (PCs) in patients with pathological stage (pStage) II or III gastric cancer (GC) who received adjuvant chemotherapy with S-1 after curative surgery. Patients and Methods: Altogether, data for 226 patients were examined retrospectively. The relationship between PCs and clinicopathological features and survival were examined. Results: Recurrence-free survival was significantly worse in the group with PCs than in the PC-negative group. On multivariate analysis, having PCs of grade 2 or more was an independent risk factor for recurrence (hazard ratio=1.721; 95% confidence intervaI=1.014-2.920; p=0.044). In addition, for each pStage analysis, having PCs of grade 2 or more was a risk factor for recurrence even in patients with pStage II GC. Conclusion: PC of grade 2 or more was an independent risk factor for recurrence in patients with pStage II GC who received adjuvant chemotherapy with S-1 after curative gastrectomy. Thus, for patients with PCs, even for those with pStage II GC, more effective adjuvant chemotherapy, such as S-1 plus docetaxel, may be needed. ER -